The enteroinvasive bacterium Shigella is a facultative intracellular bacterium known, in vitro, to invade a large diversity of cells through the delivery of virulence effectors into the cell cytoplasm via a type III secretion system (T3SS). Here, we provide evidence that the injection of T3SS effectors does not necessarily result in cell invasion. Indeed, we demonstrate through optimization of a T3SS injection reporter that effector injection without subsequent cell invasion, termed the injection-only mechanism, is the main strategy used by Shigella to target human immune cells. We show that in vitro-activated human peripheral blood B, CD4
The enteroinvasive bacterium Shigella is a facultative intracellular bacterium known, in vitro, to invade a large diversity of cells through the delivery of virulence effectors into the cell cytoplasm via a type III secretion system (T3SS). Here, we provide evidence that the injection of T3SS effectors does not necessarily result in cell invasion. Indeed, we demonstrate through optimization of a T3SS injection reporter that effector injection without subsequent cell invasion, termed the injection-only mechanism, is the main strategy used by Shigella to target human immune cells. We show that in vitro-activated human peripheral blood B, CD4
+ T, and CD8
+ T lymphocytes as well as switched memory B cells are mostly targeted by the injection-only mechanism. B and T lymphocytes residing in the human colonic lamina propria, encountered by Shigella upon its crossing of the mucosal barrier, are also mainly targeted by injection-only. These findings reveal that cells refractory to invasion can still be injected, thus extending the panel of host cells manipulated to the benefit of the pathogen. Future analysis of the functional consequences of the injection-only mechanism toward immune cells will contribute to the understanding of the priming of adaptive immunity, which is known to be altered during the course of natural Shigella infection.
Shigella | T3SS | bacterial effectors | human lymphocytes | host-pathogen cross talk T he Gram-negative enteroinvasive bacteria Shigella spp. are responsible for bacillary dysentery, an acute rectocolitis causing high levels of morbidity and mortality predominantly in children under 5 y old in low-and middle-income countries (1) . Shigella pathogenicity relies on a type III secretion system (T3SS), a device delivering bacterial effectors into the host cell cytoplasm that interfere with intracellular signaling pathways. In intestinal epithelial cells, these effectors manipulate the host cell cytoskeleton to promote bacterial internalization and reprogram cell gene expression to modulate the host innate inflammatory response, which is key for efficient establishment of Shigella infection (2) . To understand why several rounds of Shigella infection induce only a short-term protective humoral immunity and thus overcome the challenges of vaccine development (3, 4) , a better knowledge of Shigella-immune cell interactions is necessary. Over the last years, Shigella has been shown to not only target innate immune cells (5) but also to directly impact adaptive immune cells through mechanisms dependent upon its T3SS (6) (7) (8) . Our previous studies of Shigella-lymphocytes cross talks suggested that, besides invasion of these cells, injection of Shigella T3SS effectors not resulting in invasion might also occur (6) . Direct visualization of T3SS effector injection can be assessed by taking advantage of a fluorescence resonance energy transfer (FRET)-based β-lactamase assay. This translocation assay originally reported to monitor enteropathogenic Escherichia coli effector translocation (9, 10) is based on reporter bacteria expressing an effector translationally fused to the TEM-1 β-lactamase. When injected into cells loaded with the FRET substrate CCF2-AM (11), the β-lactamase cleaves the cephalosporin core of CCF2-AM, inducing a detectable shift in fluorescence from green to blue (Fig. S1 ). By using this assay, we showed injection of the Shigella T3SS effector IpgD into human T lymphocytes while using a high multiplicity of infection (MOI) and preventing invasion with the actin polymerization inhibitor cytochalasin D (6) . These findings suggested that injection of T3SS effectors might indeed be uncoupled from cellular invasion. The purpose of the current study was thus to assess the different targeting mechanisms used by Shigella while interacting with human lymphocytes, including the formal demonstration of injection occurring in the absence of invasion. To document these events in a more physiological setting (use of a lower MOI and no inhibition of bacterial invasion), we improved both parts of the injection reporter, identifying a better-secreted T3SS effector and a more efficient β-lactamase enzyme. In addition, direct distinction between invaded vs. "injected-only" cells was implemented by using imaging flow cytometry analysis combined with Shigella expressing the DsRed fluorescent protein. This strategy successfully demonstrated that the predominant Shigella-mediated mechanism to target primary human lymphocytes is indeed "injection-only."
Significance
Invasion of human intestinal epithelial cells resulting from the delivery of bacterial effectors into the host cell cytoplasm via a type III secretion system (T3SS) is the hallmark of Shigella, the causal agent of bacillary dysentery. Here, we provide evidence that human lymphocytes are mainly targeted by injection of T3SS effectors not resulting in cell invasion. These findings highlight the diversity of mechanisms triggered by Shigella to enlarge the panel of targeted cells and thus counteract host immunity, including adaptive immune responses. The potential impact of these data on vaccine design, in particular for liveattenuated vaccine candidates, deserves further investigation.
Results
Optimization of the Injection Reporter. Both parts of the injection reporter were optimized by identifying a more efficiently secreted T3SS effector and a more active β-lactamase enzyme. First, a panel of T3SS effectors was expressed as chimeric proteins fused to the β-lactamase TEM-1 (bla) in the constitutively secreting ipaD Shigella mutant strain (12) , and secretion of most of the full-length chimeric proteins was confirmed in culture supernatants (Fig. 1A) . The β-lactamase activity measured in culture supernatants, using the colorimetric substrate nitrocefin, was shown to be optimal with the enzyme fused to the first 80 aa of the T3SS effector OspD1, named OspD1sh (Fig. 1B) . Interestingly, the enzymatic activity was 35 times higher in the supernatants of ipaD strains expressing OspD1sh-bla compared with full-length OspD1-bla (Fig. 1B) . Exchange of the methionine-31 residue to leucine (M31L) abolished an alternative translation start site in the OspD1sh-bla construct, resulting in only the full-length fusion protein being expressed (Fig. 1A) , with no impact on the enzymatic activity detected in ipaD supernatants compared with strains expressing OspD1sh-bla (Fig. 1B) . As a negative control, the sequence coding for residues 2-30 of the OspD1sh-M31L-bla construct was deleted, abolishing secretion of the resulting OspD1ctrl-bla chimeric protein into ipaD supernatants (13) (Fig. 1 A and B) . Noteworthy, the enzymatic activity measured in the supernatant of ipaD bacteria expressing OspD1sh-M31L-bla was 40 times higher compared with the previously used IpgD-bla reporter construct (6) (Fig.  S2A) . Moreover, detection of T3SS-mediated effector translocation into CCF2-AM-loaded Jurkat T lymphocytes was significantly improved upon infection with WT Shigella expressing OspD1sh-M31L-bla compared with IpgD-bla (Fig. S2 B-E) .
Since the core of CCF2 is composed of a cephalosporin, a class of antibiotics most efficiently processed by class C β-lactamases (14) , members of this group were selected and their coding sequence fused in 3′ of the sequence coding for OspD1sh-M31L. The enzymatic activity measured upon incubation of CCF2 with supernatants of ipaD strains expressing these class C β-lactamases-based chimeric proteins was only 4-15% of that measured in supernatants of strains expressing TEM-1-based chimeric proteins (Fig. S3 ). OspD1sh-M31L was then translationally fused to the TEM-1 natural variant TEM-3 (also known as CTX-1) displaying increased resistance to cephalosporins (15) . In addition, the point mutation M182T known to stabilize TEM β-lactamases was introduced (16) . The resulting construct displayed a 60% increase in activity toward CCF2 in ipaD supernatants compared with strains expressing the TEM-1-based chimeric protein, and was thus selected (Fig. 1C) . Last, to discriminate between T3SS effector translocation coupled to invasion as opposed to injection-only, the sequence coding for the DsRed fluorescent protein was inserted into the reporter plasmid under the control of a constitutive promoter (Fig. S4A) . No impact on the detection of reporter translocation into Jurkat T lymphocytes was observed (Fig. 1D) . Hereafter, plasmids encoding DsRed and either the T3SS injection reporter OspD1sh-M31L-TEM3-M182T or its control counterpart OspD1ctrl-TEM3-M182T are referred to as Rep-bla and Ctrl-bla, respectively. WT strains expressing Rep-bla or Ctrl-bla were able to invade, replicate, and spread within epithelial cell monolayers to a similar extent compared with the WT strain expressing DsRed only (Fig. S4B ).
T3SS Injection Occurs Independently from Invasion in Jurkat T
Lymphocytes. Occurrence of invasion vs. injection-only events was assessed by using imaging cytometry, a technology combining flow cytometry with single-cell epifluorescence microscopy. By applying the analysis strategy described in Fig. S5 to infection of the Jurkat human T-lymphocyte cell line, three types of targeting mechanisms were identified within WT-Rep-bla-infected cells ( Fig. 2A) and their respective proportion quantified (Fig. 2B ). While confirming invasion (6), injection-only appeared to be a major targeting strategy toward these cells. Among targeted cells, those with a bacterium associated to their plasma membrane (PM-association) were considered a separated category of events since the outcome of bacterial attachment to cell surface in terms of invasion vs. injection-only is unpredictable. Similar results were obtained using multiplicity of infections (MOIs) of 50 and 10, demonstrating that the number of targeted cells had no impact on targeting mechanism proportions. As previously checked for epithelial cells, the invasiveness of WT-Rep-bla was compared with that of the control strains. Its invasion rate was about twofold lower than that of WT-Ctrl-bla or WT-DsRed (Fig. S6A) . Similar results were obtained with different sources of human primary cells, that is, blood lymphocytes ( Fig. S6B ) and lamina propria cells from colonic explants (Fig. S6C) . Consequently, quantification of injection-only vs. invasion mechanisms was considered to be relevant only when the proportion of targeted cells exceeded at least twice that of invaded cells. Bottom) of ipaD strains expressing TEM-1 chimeric proteins. The expected molecular weights of chimeric proteins were as follows (in kDa): IpgD-bla (89), OspC2-bla (85), IpaJ-bla (58), OspD1-bla (54), OspD1sh-bla (sh-bla) (38), OspD1sh-M31L-bla (sh-M31L-bla) (38) , and OspD1ctrl-bla (ctrl-bla) (35) .
(B) Measure of β-lactamase activity in the ipaD supernatants after incubation with nitrocefin. Data are from three independent experiments. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 (Student's t test compared with OspD1ctrl-bla condition, unless depicted otherwise). mononuclear cells (PBMCs) and, subsequently, B, CD4 + T, and CD8 + T lymphocytes were isolated from different donors. Lymphocyte viability and purity were systematically assessed ( Fig. S7 A-C) . For each donor, some cells were kept nonactivated while others were activated in vitro using interleukin-2 (IL-2) and protein A from Staphylococcus aureus for B lymphocytes (SAC) or phorbol 12-myristate 13-acetate (PMA) for T lymphocytes. Activation efficiency and cell viability were verified before infection (Fig. S7 B and C) .
By implementing an analysis similar to that applied to the Jurkat cell line (Fig. S5) , we showed that 30-60% of in vitroactivated primary B, CD4
+ T, and CD8 + T lymphocytes were targeted upon infection with WT-Rep-bla with a MOI of 10 ( Fig. 3A) . Regarding nonactivated lymphocytes that were infected the day following isolation, only B cells were significantly targeted by Shigella (Fig. 3B ), but to a lesser extent than their activated counterparts. Among these, switched memory B cells were preferential targets as opposed to naive B cells (Fig. 3C and Fig. S7 D and E) . Overall, incubation with Shigella had no impact on blood primary lymphocyte viability during the time frame of the experiment (Fig. S8A) . Regarding the absence of detection of nonactivated blood T lymphocytes targeted by Shigella, we cannot rule out that minor subsets, such as regulatory CD4 + T cells, might have been missed due to the analysis performed on all CD4 + T lymphocytes. Among the bloodderived activated B and T lymphocytes and the switched memory B cells, we further demonstrated that only a minor proportion of targeted cells were invaded, while injection-only constituted the main targeting mechanism (Fig. 3D) .
Human Colonic Lamina Propria B and T Lymphocytes Are Almost
Exclusively Targeted by Injection-Only. Immune cells isolated from the lamina propria of human colonic explants (Fig. 4A) , which are the first cells encountered by Shigella upon crossing the colonic epithelium barrier, were investigated. Briefly, the mucosa was dissected away from the muscle layer and epithelial cells were removed through successive EDTA incubations. Lamina propria cells were released upon collagenase treatments before CCF2-AM loading. Cells isolated through this procedure displayed variable viability from donor to donor (usually around 75%; Fig. S9A ). Only a minor contamination of epithelial cells (below 2%) was observed while more than 90% of isolated cells were CD45 + (Fig. S9B) , among which the majority was either CD19 + or CD3 + (Fig. S9C ). Following infection with WT-Repbla and WT-Ctrl-bla for 1 h at a MOI of 50, 60% of cells were still alive (Fig. S8B ) and 8-14% of live loaded cells were detected as targeted by Shigella WT-Rep-bla (Fig. 4B) .
The imaging flow cytometry procedure to quantify invaded vs. injected-only events was then implemented with some additional steps to exclude apoptotic, autofluorescent, and misshapen cells after gating on live loaded cells (Fig. S9D) . About 50-96% of the Shigella-targeted lamina propria lymphocytes were shown to be injected-only (Fig. 4C) , including CD19 + and CD3
+ lymphocytes (Fig. 4D) . Altogether, these findings revealed a thus-far-undetected mechanism used by Shigella to target host cells.
Discussion
In this study, we developed a Shigella T3SS-injection reporter tool adapted to the investigation of targeting mechanisms toward immune cells, using imaging flow cytometry to directly visualize invasion vs. injection-only events at the single-cell level. In the field of host-pathogen interactions, imaging flow cytometry has been used so far to study the intracellular fate of bacteria or parasites (17) (18) (19) (20) . This report describes an experimental strategy to simultaneously distinguish and quantify different Shigella targeting mechanisms among a given population of cells. Using this approach, we demonstrated that injection of Shigella T3SS effectors into some B-and T-lymphocytes subsets, including those relevant during natural infection of the human colon, does not necessarily result in cell invasion. We propose that this injection-only mechanism is at the core of interactions with cells refractory to invasion, thus extending the panel of host cells manipulated to the benefit of the pathogen. We hypothesize that susceptibility to Shigella T3SS effector injection, followed or not by invasion, depends on host cell morphology. This concept is based on our observations using the optimized translocation reporter of a preferential targeting of activated lymphocytes over their nonactivated counterparts, as well as switched memory B cells over naive B cells. Indeed, the amount of cytoskeleton components and the size of the cytoplasmic compartment, which are required for bacterial invasion and replication, are largely reduced in lymphocytes compared with epithelial cells but increase upon their activation (21, 22) . In particular, considering the critical role of host cytoskeleton rearrangements for Shigellainduced invasion of epithelial cells (23), we speculate that the amount of cytoskeleton components that can be hijacked by injected bacterial effectors is critical for the outcome of T3SS injection. Above the threshold required to trigger the full process of bacterial internalization, T3SS injection results in cellular invasion, while below this threshold injection-only occurs, thus permitting an increased diversity in the nature of targeted cells, beyond those sensitive to invasion. Thus far, targeting of human colonic lymphocytes by enteropathogenic bacteria has been poorly investigated. Indeed, modulation of B-and T-lymphocyte functions upon infection with Yersinia, Salmonella, EPEC, and EHEC has been studied using in vitro human cell lines or in vivo mouse models of infection (24) (25) (26) (27) (28) . In contrast, our findings constitute a description of primary human colonic lymphocyte interactions with enteropathogenic bacteria.
We consider that the current findings along with our previous report on B lymphocytes (8) leaves the door open to reexamining the current understanding of T3SS-mediated Shigella pathogenicity. We previously reported a Shigella targeting mechanism toward some B-lymphocyte subsets that is independent from both invasion and T3SS effector injection, demonstrating that these cells undergo apoptosis after activation of a TLR2-dependent signaling pathway triggered by the T3SS apparatus needle tip protein IpaD (8) . Therefore, we propose a paradigm for Shigella pathogenicity termed the "kiss-and-run" strategy. This depicts the ability of Shigella to manipulate targeted cells via a T3SS-dependent contact, which results in either no T3SS effector delivery into the host cell cytoplasm or their delivery not followed by cell invasion. Long studied for its life cycle as an intracellular pathogen based on its ability to invade almost any cell type in vitro (29, 30) , these findings highlight an overlooked aspect of Shigella's extracellular lifestyle. Considering the large panel of T3SS effectors reported to alter host cell processes (2, (31) (32) (33) , the impact of injection-only on lymphocyte functions is likely to contribute to the observed impaired priming of hostspecific immunity. It is likely that the lack of CD8 + T-cell priming reported using a mouse model of Shigella infection (suggested to be due to a T3SS effector-mediated mechanism actively interfering with antigen presentation in Shigella-infected cells) (34) might result from T3SS injection-only occurring in these cells, as reported in this work. The injection-only mechanism may also explain the Shigella-induced modulation of antimicrobial peptide production observed in noninvaded differentiated intestinal epithelial cells (35) . Future studies at the single-cell level will probe the impact of the injection-only outcome on immune cells targeted by Shigella within the human colonic mucosa and might significantly impact efforts to develop a Shigella vaccine. Indeed, in particular, the design of live, rationally attenuated, orally administered vaccine candidates will have to take into consideration the so-far-underestimated T3SS activity toward B and T lymphocytes that are key for the priming of efficient protective immunity.
Materials and Methods
Bacterial Strains and Cloning Reagents. The Shigella flexneri 5a (referred to as Shigella or S. flexneri ) M90T WT strain (36) and its derivative mutant strain ipaD (37) were grown in tryptic soy broth (TSB), supplemented when appropriate with 10 μg/mL chloramphenicol. Chemically competent Escherichia coli DH5α bacteria (Invitrogen) were used for all cloning steps and grown at 37°C in yeast tryptone medium (2xYT), supplemented when appropriate with 30 μg/mL chloramphenicol. NucleoSpin Plasmid miniprep, PCR clean-up, and gel extraction kits (Macherey-Nagel), and PureLink HiPure midiprep kit (Invitrogen) were used for DNA preparation. Restriction enzymes, T4 DNA ligase, T4 polynucleotide kinase, Taq DNA polymerase, and Phusion polymerase were purchased from Thermo Fisher Scientific.
Plasmids. The pBAD-IpgD-TEM1 plasmid was previously described (6) . Details of plasmids construction for the obtention of WT-Rep-bla are described in Supporting Information.
Bacterial Lysates and Immunoblotting. Bacterial overnight cultures were subcultured 1/50 in TSB at 37°C without antibiotics. Subcultures were spun at 9,000 × g for 1 min, and an equivalent amount of bacteria or supernatants was resuspended in Laemmli buffer (Bio-Rad). Boiled lysates were analyzed by SDS/PAGE, and proteins of interest were detected with mouse anti-β-lactamase antibody (Abcam, ab12251; or Novus Biologicals, NB120-12251; 1/1,000) and anti-mouse-HRP antibody (GE Healthcare; NXA931; 1/5,000), using film detection or Amersham Imager 600 (GE Healthcare).
Secretion Assay. Overnight cultures of ipaD bacteria were grown at 30°C and subcultured 1/50 in TSB at 37°C for 4 h without antibiotics. Subcultures were spun at 9,000 × g for 1 min, and 100 μL of supernatants at different dilutions were incubated with β-lactamase substrates: 20 μL of nitrocefin (500 μg/mL stock; EMD Millipore) or 20 μL of CCF2-FA (25 μM stock; Thermo Fisher Scientific). Hydrolysis of the colorimetric substrate nitrocefin [absorbance, 486 nm (abs 486 Human Cell Lines. Jurkat T cells (clone E6-1; ATCC TIB-152) were cultured in RPMI 1640 (Gibco) supplemented with 10% heat-inactivated FCS (HI-FCS) at 37°C in 5% CO 2 incubator. TC7 cells (a clone of Caco-2) were cultured in DMEM, 1 g/L glucose, supplemented with nonessential amino acids, glutamine (all from Gibco), and 20% HI-FCS at 37°C in 10% CO 2 incubator.
Isolation of Primary B and T Lymphocytes from Human Blood. Samples were obtained following patients' informed consent from Etablissement Français du Sang (study approved by the Institut Pasteur's ethical and medical committee, agreement HS2015-24009). PBMCs were purified by density separation on Ficoll Paque Plus (GE Healthcare) upon centrifugation at room temperature (RT) for 30 min at 800 × g without brake. Remaining red blood cells (RBCs) were lysed using RBC lysis buffer (Sigma). B, CD4
+ T, CD8 + T, naive B, and switched memory B lymphocytes were isolated using Miltenyi MicroBeads kits (B-cell kit II, CD4 + T-cell kit, CD8 + T-cell kit, naive B-cell kit II, and switched memory B-cell kit, respectively). Cells were cultured in RPMI 1640 supplemented with 10% HI-FCS, 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco) in 37°C and 5% CO 2 incubator. When indicated, activation of lymphocytes was performed for 3 d with 100 U/mL recombinant human IL-2 (Peprotech), supplemented with 0.001% (wt/vol) SAC for B lymphocytes (protein A from Staphylococcus aureus; Sigma) or 5 ng/mL PMA for T lymphocytes (PMA; Sigma). Antibodies used for purity and activation status are listed in Table S1 .
Isolation of Primary Cells from Human Colonic Specimens. Tissue specimens were obtained following patients' informed consent from Hôpital Mondor, Gastroenterology Department, Creteil, France (collaboration with A. Amiot and I. Sobhani; study approved by the Institut Pasteur's ethical and medical committee, agreement 2012-37). Samples were taken at a distance from the tumor in patients undergoing surgery for colonic cancer. Details of cell isolation are described in Supporting Information. Antibodies used for purity and targeted cell phenotyping are listed in Table S1 . Plaque Assay. Plaque assays were performed as described previously (38) , using TC7 cells cultured to confluency for 2 wk. Following 2-h infection with 10 6 bacteria at 37°C in 10% CO 2 incubator, an overlay of 0.5% agarose containing 50 μg/mL gentamycin in culture medium was poured into each well after extensive washing of the cell monolayers. Three days later, cells were fixed for 5 min in 100% ethanol and stained for 10 min in Giemsa R solution (RAL Diagnostics; diluted 1/20 in water), and plaques were enumerated.
Data Presentation and Statistical Analysis. Prism 6.0 (GraphPad Software) was used for graphs and statistical analyses. Means and SDs are represented. Unpaired two-tailed Student's t test was used to compare two groups. The Illustrator CS5 software (Adobe) was used to assemble figures.
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